# A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.

> **NCT01039610** · PHASE1 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Infections, Bacterial

## Interventions

- **DRUG:** GSK945237
- **DRUG:** Placebo
- **DRUG:** Linezolid
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT01039610
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-11
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Internal decision to progress alternate molecule with more preferable profile
- **Last updated:** 2015-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01039610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01039610, "A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01039610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*